Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium-90 resin microspheres + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Sirtex
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intra-arterial, Intravenous
01
Overview
Yttrium-90 resin microspheres + cisplatin + gemcitabine is a combination therapeutic regimen investigated for the treatment of unresectable intrahepatic cholangiocarcinoma (ICC). This sequential therapy involves selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres, followed by systemic chemotherapy with cisplatin and gemcitabine. The Y-90 resin microspheres are radioactive particles delivered via the hepatic artery to provide localized beta-radiation directly to liver tumors, a process known as radioembolization. Cisplatin is a platinum-based antineoplastic agent that induces DNA cross-linking, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. This combination approach aims to provide potent local tumor control through radiation while addressing systemic disease through chemotherapy. Clinical evaluation in phase 2 trials has demonstrated promising overall survival outcomes in patients with advanced ICC.
- Brand names
- SIR-Spheres
- Other names
- Y90-CIS-GEMY-90-CIS-GEMY 90-CIS-GEMSIRT + CIS-GEMyttrium-90 resin microspheres + cisplatin + gemcitabine hydrochloride
02
Targets
DNA polymerase familyDNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on yttrium-90 resin microspheres + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium-90 resin microspheres + cisplatin + gemcitabine.